The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Systemic Leukocyte-Directed siRNA Delivery Revealing Cyclin D1 as an Anti-Inflammatory Target
Open accessAbstract
Cyclin D1 (CyD1) is a pivotal cell cycle–regulatory molecule and a well-studied therapeutic target for cancer. Although CyD1 is also strongly up-regulated at sites of inflammation, its exact roles in this context remain uncharacterized. To address this question, we developed a strategy for selectively silencing CyD1 in leukocytes in vivo. Targeted stabilized nanoparticles (tsNPs) were loaded with CyD1–small interfering RNA (siRNA). Antibodies to β 7 integrin (β 7 I) were then used to target specific leukocyte subsets involved in gut inflammation. Systemic application of β 7 I-tsNPs silenced CyD1 in leukocytes and reversed experimentally induced colitis in mice by suppressing leukocyte proliferation and T helper cell 1 cytokine expression. This study reveals CyD1 to be a potential anti-inflammatory target, and suggests that the application of similar modes of targeting by siRNA may be feasible in other therapeutic settings.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs
Soutschek, J., Akinc, A., Bramlage, B., Charisse, K., Constien, R., Donoghue, M., Elbashir, S., Geick, A., Hadwiger, P., Harborth, J., et al. (2004) · Nature · doi:10.1038/nature03121 · Cited by 2,183
Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs
Morrissey, D. V., Lockridge, J. A., Shaw, L., Blanchard, K., Jensen, K., Breen, W., Hartsough, K., Machemer, L., Radka, S., Jadhav, V., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1122 · Cited by 1,168
Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors
Song, E., Zhu, P., Lee, S.-K., Chowdhury, D., Kussman, S., Dykxhoorn, D. M., Feng, Y., Palliser, D., Weiner, D. B., Shankar, P., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1101 · Cited by 1,021
Minireview: Cyclin D1: Normal and Abnormal Functions
Fu, M., Wang, C., Li, Z., Sakamaki, T., & Pestell, R. G. (2004) · Endocrinology · doi:10.1210/en.2004-0959 · Cited by 966
Schiffelers, R. M. (2004) · Nucleic Acids Research · doi:10.1093/nar/gnh140 · Cited by 901
Progress towards in Vivo Use of siRNAs
Behlke, M. A. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.01.001 · Cited by 677
Protamine sulfate enhances lipid-mediated gene transfer
Sorgi, F., Bhattacharya, S., & Huang, L. (1997) · Gene Therapy · doi:10.1038/sj.gt.3300484 · Cited by 451
Cyclin D1 serves as a cell cycle regulatory switch in actively proliferating cells
Stacey, D. W. (2003) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(03)00008-5 · Cited by 439
Heidel, J. D., Yu, Z., Liu, J. Y.-C., Rele, S. M., Liang, Y., Zeidan, R. K., Kornbrust, D. J., & Davis, M. E. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701458104 · Cited by 382
Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo
Takeshita, F., Minakuchi, Y., Nagahara, S., Honma, K., Sasaki, H., Hirai, K., Teratani, T., Namatame, N., Yamamoto, Y., Hanai, K., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501753102 · Cited by 355
Cited by
Knocking down barriers: advances in siRNA delivery
Whitehead, K. A., Langer, R., & Anderson, D. G. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2742 · Cited by 3,115
Reactive Oxygen Species (ROS)-Based Nanomedicine
Yang, B., Chen, Y., & Shi, J. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00626 · Cited by 2,443
Pharmacokinetics and Biodistribution of Nanoparticles
Li, S.-D., & Huang, L. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800049w · Cited by 1,568
The current state and future directions of RNAi-based therapeutics
Setten, R. L., Rossi, J. J., & Han, S.-P. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0017-4 · Cited by 1,443
Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms
Akinc, A., Querbes, W., De, S., Qin, J., Frank-Kamenetsky, M., Jayaprakash, K. N., Jayaraman, M., Rajeev, K. G., Cantley, W. L., Dorkin, J. R., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.85 · Cited by 1,261
The promises and pitfalls of RNA-interference-based therapeutics
Castanotto, D., & Rossi, J. J. (2009) · Nature · doi:10.1038/nature07758 · Cited by 1,221
Therapeutic targeting of microRNAs: current status and future challenges
Li, Z., & Rana, T. M. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4359 · Cited by 1,033
Therapeutic siRNA silencing in inflammatory monocytes in mice
Leuschner, F., Dutta, P., Gorbatov, R., Novobrantseva, T. I., Donahoe, J. S., Courties, G., Lee, K. M., Kim, J. I., Markmann, J. F., Marinelli, B., et al. (2011) · Nature Biotechnology · doi:10.1038/nbt.1989 · Cited by 839
Knocking down disease: a progress report on siRNA therapeutics
Wittrup, A., & Lieberman, J. (2015) · Nature Reviews Genetics · doi:10.1038/nrg3978 · Cited by 804
Current prospects for RNA interference-based therapies
Davidson, B. L., & McCray, P. B. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2968 · Cited by 761
Wilson, D. S., Dalmasso, G., Wang, L., Sitaraman, S. V., Merlin, D., & Murthy, N. (2010) · Nature Materials · doi:10.1038/nmat2859 · Cited by 747
siRNA delivery systems for cancer treatment
Oh, Y.-K., & Park, T. G. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.04.018 · Cited by 645
Breaking down the barriers: siRNA delivery and endosome escape
Dominska, M., & Dykxhoorn, D. M. (2010) · Journal of Cell Science · doi:10.1242/jcs.066399 · Cited by 630
Remotely Triggerable Drug Delivery Systems
Timko, B. P., Dvir, T., & Kohane, D. S. (2010) · Advanced Materials · doi:10.1002/adma.201002072 · Cited by 614
Factors Controlling Nanoparticle Pharmacokinetics: An Integrated Analysis and Perspective
Moghimi, S. M., Hunter, A. C., & Andresen, T. L. (2012) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010611-134623 · Cited by 545
Kedmi, R., Ben-Arie, N., & Peer, D. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.05.027 · Cited by 546
Self-citationPark, J., Wrzesinski, S. H., Stern, E., Look, M., Criscione, J., Ragheb, R., Jay, S. M., Demento, S. L., Agawu, A., Licona Limon, P., et al. (2012) · Nature Materials · doi:10.1038/nmat3355 · Cited by 494
Self-assembled RNA interference microsponges for efficient siRNA delivery
Lee, J. B., Hong, J., Bonner, D. K., Poon, Z., & Hammond, P. T. (2012) · Nature Materials · doi:10.1038/nmat3253 · Cited by 494
Nanoparticle Hydrophobicity Dictates Immune Response
Moyano, D. F., Goldsmith, M., Solfiell, D. J., Landesman-Milo, D., Miranda, O. R., Peer, D., & Rotello, V. M. (2012) · Journal of the American Chemical Society · doi:10.1021/ja2108905 · Cited by 478
Self-citationWoodrow, K. A., Cu, Y., Booth, C. J., Saucier-Sawyer, J. K., Wood, M. J., & Mark Saltzman, W. (2009) · Nature Materials · doi:10.1038/nmat2444 · Cited by 438
Chemically modified siRNA: tools and applications
Watts, J. K., Deleavey, G. F., & Damha, M. J. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2008.05.007 · Cited by 431
Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides
Juliano, R., Alam, M. R., Dixit, V., & Kang, H. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn342 · Cited by 429
Nanoparticles and their applications in cell and molecular biology
Wang, E. C., & Wang, A. Z. (2014) · Integrative Biology · doi:10.1039/c3ib40165k · Cited by 415
RNA-Based Therapeutics: From Antisense Oligonucleotides to miRNAs
Bajan, S., & Hutvagner, G. (2020) · Cells · doi:10.3390/cells9010137 · Cited by 393
Cytosolic delivery of nucleic acids: The case of ionizable lipid nanoparticles
Schlich, M., Palomba, R., Costabile, G., Mizrahy, S., Pannuzzo, M., Peer, D., & Decuzzi, P. (2021) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10213 · Cited by 387
Self-citationA review of nanocarriers for the delivery of small interfering RNA
Kesharwani, P., Gajbhiye, V., & Jain, N. K. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.06.068 · Cited by 368
Targeting of tetraspanin proteins — potential benefits and strategies
Hemler, M. E. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2659 · Cited by 345
Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice
Judge, A. D., Robbins, M., Tavakoli, I., Levi, J., Hu, L., Fronda, A., Ambegia, E., McClintock, K., & MacLachlan, I. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37515 · Cited by 336
Development of Lipidoid–siRNA Formulations for Systemic Delivery to the Liver
Akinc, A., Goldberg, M., Qin, J., Dorkin, J. R., Gamba-Vitalo, C., Maier, M., Jayaprakash, K. N., Jayaraman, M., Rajeev, K. G., Manoharan, M., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.36 · Cited by 323
A modular platform for targeted RNAi therapeutics
Kedmi, R., Veiga, N., Ramishetti, S., Goldsmith, M., Rosenblum, D., Dammes, N., Hazan-Halevy, I., Nahary, L., Leviatan-Ben-Arye, S., Harlev, M., et al. (2018) · Nature Nanotechnology · doi:10.1038/s41565-017-0043-5 · Cited by 320
Self-citationEfficient and targeted delivery of siRNA in vivo
Shim, M. S., & Kwon, Y. J. (2010) · The FEBS Journal · doi:10.1111/j.1742-4658.2010.07904.x · Cited by 309
Engineering RNA for Targeted siRNA Delivery and Medical Application
Guo, P., Coban, O., Snead, N. M., Trebley, J., Hoeprich, S., Guo, S., & Shu, Y. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.03.008 · Cited by 300
A status report on RNAi therapeutics
Vaishnaw, A. K., Gollob, J., Gamba-Vitalo, C., Hutabarat, R., Sah, D., Meyers, R., de Fougerolles, T., & Maraganore, J. (2010) · Silence · doi:10.1186/1758-907x-1-14 · Cited by 297
Nanoparticles for Imaging, Sensing, and Therapeutic Intervention
Bogart, L. K., Pourroy, G., Murphy, C. J., Puntes, V., Pellegrino, T., Rosenblum, D., Peer, D., & Lévy, R. (2014) · ACS Nano · doi:10.1021/nn500962q · Cited by 295
Self-citationRole of β7 Integrins in Intestinal Lymphocyte Homing and Retention
Gorfu, G., Rivera-Nieves, J., & Ley, K. (2009) · Current Molecular Medicine · doi:10.2174/156652409789105525 · Cited by 292
Going beyond the liver: progress and challenges of targeted delivery of siRNA therapeutics
Lorenzer, C., Dirin, M., Winkler, A.-M., Baumann, V., & Winkler, J. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.02.003 · Cited by 284
Courties, G., Heidt, T., Sebas, M., Iwamoto, Y., Jeon, D., Truelove, J., Tricot, B., Wojtkiewicz, G., Dutta, P., Sager, H. B., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.023 · Cited by 278
Macrophage-Secreted Factors Promote a Profibrotic Phenotype in Human Preadipocytes
Keophiphath, M., Achard, V., Henegar, C., Rouault, C., Clément, K., & Lacasa, D. (2009) · Molecular Endocrinology · doi:10.1210/me.2008-0183 · Cited by 278
Gou, S., Huang, Y., Wan, Y., Ma, Y., Zhou, X., Tong, X., Huang, J., Kang, Y., Pan, G., Dai, F., et al. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.05.012 · Cited by 277
RNAi and small interfering RNAs in human disease therapeutic applications
Lares, M. R., Rossi, J. J., & Ouellet, D. L. (2010) · Trends in biotechnology · doi:10.1016/j.tibtech.2010.07.009 · Cited by 277
Gold, Poly(β-amino ester) Nanoparticles for Small Interfering RNA Delivery
Lee, J.-S., Green, J. J., Love, K. T., Sunshine, J., Langer, R., & Anderson, D. G. (2009) · Nano Letters · doi:10.1021/nl9009793 · Cited by 276
Nanomedicine in cancer therapy: Innovative trends and prospects
Blanco, E., Hsiao, A., Mann, A. P., Landry, M. G., Meric‐Bernstam, F., & Ferrari, M. (2011) · Cancer Science · doi:10.1111/j.1349-7006.2011.01941.x · Cited by 265
Qhattal, H. S. S., & Liu, X. (2011) · Molecular Pharmaceutics · doi:10.1021/mp2000428 · Cited by 254
Nano- and microparticulate drug carriers for targeting of the inflamed intestinal mucosa
Collnot, E.-M., Ali, H., & Lehr, C.-M. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.01.028 · Cited by 254
Lipid-based nanoparticle formulations for small molecules and RNA drugs
Ickenstein, L. M., & Garidel, P. (2019) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2019.1669558 · Cited by 193
“This number can be achieved by the successful delivery of one single LNP to its target since up to 4000 siRNA molecules are loaded in each LNP [221].”
BackgroundCohen, Z. R., Ramishetti, S., Peshes-Yaloz, N., Goldsmith, M., Wohl, A., Zibly, Z., & Peer, D. (2015) · ACS Nano · doi:10.1021/nn506248s · Cited by 182
Self-citationMacrophage-based nanotherapeutic strategies in ulcerative colitis
Zhang, J., Zhao, Y., Hou, T., Zeng, H., Kalambhe, D., Wang, B., Shen, X., & Huang, Y. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.01.047 · Cited by 160
Oral colon-specific therapeutic approaches toward treatment of inflammatory bowel disease
Xiao, B., & Merlin, D. (2012) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2012.730517 · Cited by 145
Personalized Hydrogels for Engineering Diverse Fully Autologous Tissue Implants
Edri, R., Gal, I., Noor, N., Harel, T., Fleischer, S., Adadi, N., Green, O., Shabat, D., Heller, L., Shapira, A., et al. (2019) · Advanced Materials · doi:10.1002/adma.201803895 · Cited by 128
Self-citationPrecision Nanomedicine in Neurodegenerative Diseases
Goldsmith, M., Abramovitz, L., & Peer, D. (2014) · ACS Nano · doi:10.1021/nn501292z · Cited by 124
“molecules such as proteins and polynucleotides.(41) Nanoparticles have been successfully modified with In this issue of ACS”
BackgroundSelf-citationLiposomal gene delivery mediated by tissue-engineered scaffolds
Kulkarni, M., Greiser, U., O’Brien, T., & Pandit, A. (2010) · Trends in Biotechnology · doi:10.1016/j.tibtech.2009.10.003 · Cited by 81
ScFv‐Decorated PEG‐PLA‐Based Nanoparticles for Enhanced siRNA Delivery to Her2+ Breast Cancer
Dou, S., Yang, X., Xiong, M., Sun, C., Yao, Y., Zhu, Y., & Wang, J. (2014) · Advanced Healthcare Materials · doi:10.1002/adhm.201400037 · Cited by 39
Pandey, M., Ojha, D., Bansal, S., Rode, A. B., & Chawla, G. (2021) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2021.101003 · Cited by 23
(2012) · Digital Access to Scholarship at Harvard (DASH) (Harvard University)
Metadata
- Authors
- Peer, D., Park, E. J., Morishita, Y., Carman, C. V., & Shimaoka, M.
- Venue
- Science
- Published
- 2008-02
- Volume
- 319
- Issue
- 5863
- Pages
- 627-630
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2060056553
- Cited by
- 493
- References
- 20
- FWCI
- 21.22
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.